← Katalog Appraisal
TAPublishedBlood and immune system conditions / Blood and bone marrow cancers· 2024-05-29
TA978
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
0 item